Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-03-31 Regulatory Filings
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Kazia Therapeutics Limited, with the SEC. It contains a press release about the sale of intellectual property and trademark rights, attached as Exhibit 99.1. The document is short (2057 characters) and primarily serves to report this press release to the SEC. It does not contain detailed financial data, management discussion, or comprehensive report content. According to the rules, such filings that provide an announcement or incorporation by reference of a press release or report, without substantive financial or operational data, should be classified as Regulatory Filings (RNS).
2025-03-31 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-03-19 English
6-K
Report Publication Announcement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Kazia Therapeutics Limited, with the SEC. It states that the company provided its Annual Report to shareholders for the fiscal year ended June 30, 2024, and that the Annual Report is attached as Exhibit 99.1. The document itself is short (1390 characters) and primarily serves as a notification that the Annual Report has been furnished. According to the 'Menu vs Meal' rule, such a short document announcing the availability of a report should be classified as a Report Publication Announcement (RPA), not as the Annual Report (10-K) itself. Therefore, the correct classification is RPA with high confidence.
2025-03-13 English
424B3
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes a prospectus supplement and a press release about a research grant received for a therapeutic study. The document does not contain financial statements or detailed financial analysis but rather updates and supplementary information related to a registration statement and a current report. It is not an annual report, interim report, earnings release, or any other detailed financial report. The document is primarily a regulatory filing providing supplemental information and a press release. Therefore, it fits best under the category of Regulatory Filings (RNS).
2025-02-21 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes a press release about a research grant received for a therapeutic study, and it references a prospectus supplement related to a registration statement. The document does not contain financial statements or detailed financial analysis but rather provides an update on corporate activities and research collaborations. It is not an annual or interim report, earnings release, or any other detailed financial report. It is a regulatory filing providing current information and updates, typical of Form 6-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-02-20 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Kazia Therapeutics Limited, with the SEC. It contains a press release about receiving a research grant, which is attached as Exhibit 99.1. The document is short (2172 characters) and primarily serves to report this press release. There is no substantive financial data, detailed financial results, or comprehensive report content. It is an informational filing to update the market and regulators about a corporate event, not a full financial report or earnings release. According to the rules, such filings that provide updates or press releases without detailed financial data or analysis are best classified as Regulatory Filings (RNS).
2025-02-20 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.